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Abstract
Background: Marrow-derived stromal cells (MSCs) maintain the capability of self-renewal and
differentiation into multiple lineages in adult life. Age-related changes are recognized by a decline
in the stemness potential that result in reduced regeneration potential of the skeleton. To explore
the molecular events that underline skeletal physiology during aging we catalogued the profile of
gene expression in ex vivo cultured MSCs derived from 3 and 15 month old rats. The ex vivo cultured
cells were analyzed following challenge with or without Dexamethasone (Dex). RNA retrieved
from these cells was analyzed using Affymetrix Gene Chips to compare the effect of Dex on gene
expression in both age groups.
Results: The molecular mechanisms that underline skeletal senescence were studied by gene
expression analysis of RNA harvested from MSCs. The analysis resulted in complex profiles of gene
expression of various differentiation pathways. We revealed changes of lineage-specific gene
expression; in general the pattern of expression included repression of proliferation and induction
of differentiation. The functional analysis of genes clustered were related to major pathways; an
increase in bone remodeling, osteogenesis and muscle formation, coupled with a decrease in
adipogenesis. We demonstrated a Dex-related decrease in immune response and in genes that
regulate bone resorption and an increase in osteoblastic differentiation. Myogenic-related genes
and genes that regulate cell cycle were induced by Dex. While Dex repressed genes related to
adipogenesis and catabolism, this decrease was complementary to an increase in expression of
genes related to osteogenesis.
Conclusion: This study summarizes the genes expressed in the ex vivo cultured mesenchymal cells
and their response to Dex. Functional clustering highlights the complexity of gene expression in
MSCs and will advance the understanding of major pathways that trigger the natural changes
underlining physiological aging. The high throughput analysis shed light on the anabolic effect of Dex
and the relationship between osteogenesis, myogenesis and adipogenesis in the bone marrow cells.
Background
The stromal compartment of the bone marrow contains
mesenchymal stem and progenitor cells with high prolif-
erating capacity in addition to cells at different stages of
maturation. The mesenchymal cells are at the front of cell
research today which differentiate in vitro and in vivo to
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multiple lineages including fibroblasts, adipocytes, carti-
lage, myogenic, and osteogenic cells [1-7]. MSCs also har-
bor the potential of trans-differentiation to many different
lineages, thus providing a possible source of progenitors
for cell therapy and tissue repair including bone, cartilage,
cardiac, pancreas regeneration and neural injury repair
[8]. Cell differentiation through distinct maturational
stages involves coordination and activation of different
sets of genes. Progenitor cells derived from the stroma
compartment of the bone marrow differentiate under the
control of transcription factors, which serve as lineage spe-
cific master genes for discrete differentiation steps. Defini-
tion of the key differentiation signals is important in order
to induce the desired ex vivo lineage-specific maturation
pathways.
Age related hormonal changes, for example a decline in
sex hormones levels, are associated with a decrease in the
number and activity of osteogenic cells and an increase in
numbers of adipocytes [9-15]. It is generally accepted that
these changes arise from a decrease in the stemness poten-
tial accompanied by a decrease in the proliferative ability
and osteogenic capacity of the bone marrow cells [11,15-
18]. The changes in stemness with age result in reduced
osteogenesis and increased adipogenesis, affecting the
skeletal structure and the immune system. Age-related
changes associated with osteoporosis were previously
studied by us in animal models [15,19] and in ex vivo cul-
tures of stromal cells [20]. It is clear that the physiological
status of the body affects the skeleton at the cellular level,
but the underlying molecular mechanism remains unre-
solved.
The action of native or pharmacological glucocorticoid
hormones, such as Dexamethasone (Dex), is mediated via
glucocorticoid receptors (GRs). Dex is recognized by mul-
tiple effects on a wide range of tissues and physiological
conditions in the body [21]. Dexamethasone promotes
osteogenesis in vitro [22], and induces the expression of
osteogenic markers in MSCs [20,23-25].
In this study, we analyze the molecular changes in aged
rats that influence the cellular potential and the response
to Dex. We used GeneChip technology to explore the
molecular changes regulating the processes that govern
the commitment and differentiation of the MSCs in
young and aged animals. This approach enables us to ana-
lyze genome-wide patterns of mRNA expression and to
provide an efficient access to genetic information. We
compared gene profiling between MSCs cultured ex vivo
from young and old rats (3 and 15 month old). The cells
were maintained in vitro and maintained in presence or
absence of Dex. The RNA extracted was analyzed to assess
the transcriptome profile of MSCs. From the microarrays
we further analyzed the lineage-specific gene expression in
the MSCs enabling us to reveal genome-wide patterns of
mRNA expression and to sort the gene profiles that govern
various cell activities.
Results
The GeneChip analysis
Primary marrow stromal cells (MSCs) derived from the
bone marrow include stem and progenitor cells with high
proliferating capacity. We have earlier studied MSC in rat
[19] and mouse [4,15] models and demonstrated that the
decline in stemness with aging is associated with bone
atrophy, increase of adipocytes and augmentation of T-
lymphopoiesis.
The present study aimed to compare the profile of genes
expressed by cultured MSCs derived from 3 and 15 month
old rats, expanded in vitro and treated or untreated with
Dex. We used microarray technology to compare the tran-
scriptome profile between cultured MSCs from 4 experi-
mental groups: young Y (3 month) and old O (15 month)
rats that were treated (YT, OT) or untreated (YU, OU) with
Dex. The molecular analysis represents snapshot of cellu-
lar states from these rats and reflects their potential for tis-
sue differentiation. The analysis resulted with 10290
Probe Sets (PS) that changed with fold change of two or
higher. The PS clustering attempts to elucidate the pattern
of gene expression which is unique to MSCs.
Genes differentially expressed between experimental 
groups
The gene expression was studied for RNA from each age
group, and the overlap between them was calculated. RNA
was retrieved from four groups of cells according to treat-
ment and animal age: untreated cells from 3 month old
rats (young untreated – YU – 1), 15 month old rats (old
untreated – OU – 2) and treated cells from young and old
rats (YT – 3, OT – 4). Differentially expressed PS were
marked either as increasing or decreasing according to
expression ratios between Dex-treated and untreated cells.
In cells derived from young rats, the analysis resulted in
3318 differentially expressed PS, 1604 increasing (YI) and
1714 decreasing (YD). In cells derived from old rats, 2725
PS were differentially expressed – 1314 increasing (OI),
1411 decreasing (OD) following treatment.
A total of 888 PS increased and 1077 PS decreased in cells
derived from both young and old rats due to the Dex treat-
ment. The analysis of differentially expressed PS was
repeated for fold change of 3, 4 and 5 and resulted in
smaller numbers of differentially expressed PS. The
number of PS differentially expressed at fold change
higher then 2 decreased, but the ratio of expressed PS in
both ages versus PS expressed in cells derived from young
or old rats did not change much, indicating a common
response to Dex in both ages (Figure 1).BMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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The ratio of PS changed in both groups relative to PS
changed in cells from old rats remained constant. The
ratio of PS increased in both groups (BI) relative to PS
increased in old (OI) and the ratio of decreasing PS (BD/
OD) remained at about 60% and 70%, respectively. The
PS increased in both groups (BI) relative to PS increased
in young (YI) lowered from 55% to 32% as the number of
differentially expressed PS decreased (due to increasing
fold change). The ratio of PS decreased in both groups
(BD) relative to PS that decreased in young (YD) lowered
from 63% to 48% as the number of PS in general
decreased.
Clustering analysis
PS were clustered to profile distinct Dex effect for both age
groups; 4060 PS were differentially expressed, up or down
regulated more than 2-fold, due to the Dex treatment in
cells derived from young and old rats. The analysis
resulted in six clusters that were divided into PS that
increased (A-C) or decreased (D-F) (Figure 2). Cluster A
(704 PS) represents PS that increased in cells derived from
young rats, Cluster B, represents 420 PS increased in old
rats, and PS that increased in cells from both age groups
are included in Cluster C (888 PS). PS that decreased in
cells derived from young rats are put in Cluster D (631
PS), PS that decreased in cells from old rats – in Cluster E
(322 PS), and Cluster F (1071 PS) presents PS that
decreased in cells from both age groups. A small number
of PS increased in cells from young rats and decreased in
cells from old rats (12 PS) or the opposite pattern of
expression (6 PS) (data not shown). PS who had a known
Gene ID were analyzed for functional properties of the
genes.
Functional pathways involved in mesenchymal cells 
differentiation
Comparing gene expression profiles between Dex-treated
or untreated cultured cells obtained from young and old
rats results with clustering of 6 groups (Figure 2) analyzed
for statistically significant functions, using the GOTM.
This analysis shows functions affecting response to Dex
and differentiation of skeletal and bone marrow cells.
Tables 1 and 2 describe the major functions that have a
high fold change and highlight various differentiation
pathways of mesenchymal cells affected by Dex treatment.
Series of genes increased following Dex treatment of MSCs
are represented in clusters A-C (Figure 2): genes increased
in cells derived from young rats (A), in cells derived from
old rats (B) and genes increased in cells derived from both
age groups (C) (Table 1). The overall gene expression
reflects the Dex-related shift of cellular metabolism,
Table 1: Genes induced by Dexamethasone in MSCs
Function p-value Up to fold change Number of Genes
Cluster A – Dex induced genes in MSCs derived from young rats
Angiogenesis 0.00125 5 5
Bone remodeling 0.00448 2 4
Cluster C – Dex induced genes in MSCs derived from young and old rats
Cell growth 2.36E-06 5 11
Regulation of cell cycle 0.00418 4 13
Muscle development 0.00555 4 7
Muscle contraction 0.00157 4 4
Cytoskeleton 0.00868 2 19
Actin cytoskeleton 0.00803 4 7
Structural constituent of 
cytoskeleton
0.00533 4 4
Ratio of PS differentially expressed in both age groups vs.  each age group Figure 1
Ratio of PS differentially expressed in both age 
groups vs. each age group. BI – PS that increased in cells 
derived in both age groups, YI – PS that increased in cells 
derived from young rats, OI – PS that increased in cells from 
old rats. BD, YD, OD – PS that decreased in cells from both 
age groups, in cells from young and old rats respectively. The 
graph presents ratios for multiple fold changes: 2,3,4,5. BI/YI 
and BD/YD (white bar), BI/OI and BD/OD (grey bar).
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which results in a decrease in proliferation, coupled with
differentiation of MSCs to osteogenic and myogenic direc-
tions and a repression of the adipogenic pathway.
Cluster A (genes that increased only in cells derived from
young rats) includes VEGF, Id1, Madh5 and beta-catenin
which are related to angiogenesis (p = 0.00125), implying
that neovascularization is linked to osteoblast maturation
and bone remodeling (p = 0.00448), which included the
genes PTHr1, IBSP, Madh5 and bone ECM protein Mepe.
These genes are related to osteogenesis and indicate an
osteogenic differentiation of these cells. Human and
mouse orthologs disclosed components of ECM structural
constituent such as collagens IV, V, VI and laminin (p =
0.00287). Dex has an anabolic effect on cells from young
rats that increases osteogenesis-related markers, while
such an effect was undetected in cells derived from old rats
and is possibly related to the decrease in bone formation
associated with aging.
Cluster C presents genes that increased due to Dex treat-
ment in cells derived from both young and old rats (Table
1) which are related to cell growth (p = 2.36E-06), regula-
tion of cell cycle (p = 0.00418), muscle differentiation and
contraction (p = 0.00555, p = 0.00157), cytoskeletal com-
ponents (p = 0.00868) including structural constituents of
the cytoskeleton and actins (p = 0.00533, p = 0.00803). A
reciprocal relationship of proliferation and differentiation
is recognized by a decrease in genes that activate prolifer-
ation as cells differentiate. Human and mouse orthologs
of the rat genes are related to the dystrophin complex (p =
0.00311) which plays a role in development of skeletal
muscle. An increase in muscle related genes due to Dex
indicates the potential of mesenchymal stem cells to dif-
ferentiate into myotubes.
Genes decreased following Dex treatment are clustered in
D-F (Figure 2) for cells derived from young rats (D), old
rats (E) and from both age groups (F) (Table 2). Genes
repressed following Dex treatment in cells derived from
young rats are related to adipocyte differentiation, regula-
tion and function (Table 2, Cluster D). PPARγ and CEBPα
are TFs essential for adipocyte differentiation (p =
0.0056).  PPARγ  maintains adipogenesis affecting early
differentiation and survival of mature adipocytes and
CEBPα  is activated later than PPARγ. An inhibition of
PPARγ  and  CEBPα  in response to Dex results with a
decrease of adipogenesis. The effect of Dex in lowering the
adipogenesis (Table 2, cluster D) is complementary to
increasing the osteogenesis (Table 1, cluster A).
Cluster F (Table 2) summarizes genes repressed by Dex
treatment in cells derived from both age groups and
includes genes related to defense response (p = 0.0006).
We noticed a decrease in RAS signaling genes (p =
0.00016), such as Nras, Kras2, Grb2  and Aps, which is
complimentary to the proliferation and differentiation
genes induced by Dex (Table 1, Cluster C). Dex repressed
genes related to catabolism (p = 0.00027) and proteolysis
(p = 0.00312), including mainly lysosomal (p = 1.4E-07)
hydrolases (p = 0.00019). The suppression of adipogenic
differentiation is monitored by the decrease of genes
related to lipid binding (p = 0.00024), lipid transport (p
= 0.0096) and diacylglycerol binding (p = 0.00474)
including genes such as FABP-4  (aP-2) and lipoprotein
lipase (Lpl). Protein Kinase C isoforms comprised some of
the genes identified as lipid binding cluster. The variants
of this gene have a role in muscle differentiation and
mediate PTH receptor action in repressing adipogenesis
and inducing osteogenesis.
The functional analysis of the clusters resulted in major
pathways – an increase in osteogenesis and muscle forma-
tion, coupled with a decrease in adipogenesis. We selected
the genes representing these differentiation pathways
(Table 3) and divided them into clusters and functional
groups. Genes which increased only in cells from young
rats belong to the functional group of bone remodeling
Table 2: Genes repressed by Dexamethasone in MSCs
Function p-value Up to fold change Number of Genes
Cluster D – Dex repressed genes in MSCs derived from young rats
Adipocyte differentiation 0.00563 2 2
Cluster F – Dex repressed genes in MSCs derived from young & old rats
RAS protein signal transduction 0.00016 4 4
Defense response 0.00060 5 20
Catabolism 0.00027 4 31
Peptidase activity 0.00282 4 21
Lipid binding 0.00024 5 12
Diacylglycerol binding 0.00474 2 5
Lipid transport 0.00960 3 5
Hydrolase activity 0.00019 4 55
Lysosome vacuole 1.4E-07 5 13BMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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and angiogenesis. Genes that increased in both cells
derived from young and old rats are related to muscle
development and cell cycle. Other genes that decreased
only in cells derived from young rats are related to adi-
pocyte differentiation and genes that decreased in both
groups are related to lipid binding, catabolic peptidases,
immune response and RAS signaling. To validate the
results from the gene array we employed RT-PCR analysis
summarized in Figure 3 (p values are specified in the leg-
end). Analyses were performed for the expression of BSP,
Biglycan and BMP4 to follow osteogenic pathway; desmin
and actin γ2 – to follow the effect of age and Dex on the
cell potential to differentiate to myoblasts. AP-2, LPL and
Adipsin were used to follow adipogenesis. Analyzed mark-
ers showed age and Dex related changes detected with a
similar fold change levels for both RT-PCR and array anal-
ysis. The expression of GR was analyzed to verify that the
response to Dex resulted with down regulation of the
receptor. The expression level of GR  decreased in cells
from both age groups – the ratios were 0.4 and 0.54 on the
chip, and 0.44 and 0.42 by RT-PCR. The fold change for
desmin on the chip array was 2.4 for cells derived from
young rats and 2.36 for cells derived from old rats and 1.9
and 2.05 by RT-PCR, respectively. AP-2  expression
decreased on the chip (0.04 and 0.01), and by RT-PCR
(0.2 and 0.12). Dex triggered an increase in the osteogenic
related genes that was more prominent in young animals.
An increase was noted in muscle-related genes in cells
from both age groups; and a decrease in genes related to
the lipid metabolism. The expression level of these genes
Illustration of the clusters A to E Figure 2
Illustration of the clusters A to E. Four groups of analyzed samples are presented: 1 – young untreated (YU), 2 – old 
untreated (OU), 3 – young treated (YT), 4 – old treated (OT). The mean of each PS was standardized to 0, and the standard 
deviation was 1. The clusters included PS increased in cells from young rats (A), increased in cells from old rats(B), increased in 
cells from both age groups (C), decreased in cells from young rats(D), decreased in cells from old rats (E), decreased in cells 
from both age groups (F). Expression patterns of all clusters are presented with error bars. PS at levels lower than zero indi-
cates the repressed expression and PS at levels above zero indicates the induced expression.BMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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behaved in a similar manner on the chip and when
checked by RT-PCR. The comparison between the two
methods confirmed the biological effect of Dex on cells
from young and old rats.
Discussion
Mesenchymal stem cells have an ability to differentiate
into multiple lineages including adipocytes, myocytes and
bone forming cells [1-7]. Aging affects the bone marrow
microenvironment in multiple ways, repressing the
"stemness" of cells which results in a decrease in bone for-
mation. The number of precursor cells of the hematopoi-
etic and osteogenic cells as well as their proliferative
ability decrease with aging [10,11]. Although there are
some contradictory findings in the literature related to
proliferative and osteogenic potential, some of them rely
on studies performed with total bone marrow population
[17,26]. Other experiments [9-15], including ones in our
laboratory [15,19], have focused on the mesenchymal
stem cells and have shown a decrease in the stemness
potential followed by a decline in the proliferative and
osteogenic capacities. Consequently the molecular mech-
anism of the decrease in stemness associated with a
decrease in bone formation with aging is yet unclear.
To better understand the molecular mechanisms govern-
ing the cellular changes we profiled the response of ex vivo
cultured stromal cells challenged by Dex and compared
cells derived from young and old rats. The gene expression
profile revealed overlap of Dex action between the MSC
derived from the two age groups. The functional analysis
of the differentially expressed genes highlighted a general
shift in the metabolism of the MSCs which included
repression of proliferation and was complemented by
induction of differentiation. Specifically, we monitored
genes related to induction of myogenic and osteogenic
differentiation coupled with a decrease in adipogenesis.
The results presented show a decrease in proliferation
coupled with an increase in muscle related genes,
observed in both age groups (Cluster C). The expression
of muscle related genes indicates that the potential of
mesenchymal stem cells to differentiate to myotubes is
enhanced by Dex, which was reported earlier [27]. A recip-
rocal relationship of proliferation and differentiation is
known – acquisition of differentiated phenotype is
accompanied by a decrease in cells' proliferation poten-
tial, a relationship which is well documented for osteob-
lasts [28] and for myoblasts [29]. Dysfunction of tumor
suppressor proteins results in attenuation of osteogenesis
and myogenesis, in vivo [30,31] and in vitro [32]. It was
shown that myoblasts lacking Rb failed to differentiate
into myotubes even when transfected with MyoD, an
essential transcription factor for myogenesis [33]. In the
MSCs analyzed in the present study, Dex decreased prolif-
eration and triggered myogenesis. In addition, the genes
induced are known to play a role in osteogenesis, which
was also induced. Few examples are shown by the expres-
sion of PDGFa [34], TGFb3 and p53 [32], genes known to
play a role in osteogenesis [35] in addition to myogenic
differentiation.
Aging is accompanied by a reduced stemness potential of
MSCs resulting in a decrease of osteogenesis and replace-
ment of bone marrow with fat cells. This phenomena is
associated with osteoporosis [36] and overall reduction of
osteogenic stem cells with aging [12]. In agreement with
this, in our study the cells derived from young rats, but not
the ones derived from old rats, responded to Dex with an
increase in genes involved in bone remodeling, angiogen-
esis and a decrease in genes related to adipocyte differen-
tiation.
Genes increased in cells derived from young rats (Cluster
A) were related to bone remodeling and included PTHr1,
BSP, Madh5, Mepe, byglican and BMP4 which are expressed
in osteoblasts during differentiation and bone regenera-
tion [35,37,38], indicating an anabolic effect of Dex on
the cells derived from young rats. The anabolic effect of
Dex is known, as demonstrated by increases in the expres-
sion of bone related genes including BSP in rat osteoblas-
tic cells [39,40]. Such an effect was not observed on cells
derived from old rats, which might be related to the
decrease in bone formation potential recognized with
aging. Neovascularization is linked to osteoblast matura-
tion and bone deposition [41]. The angiogenesis func-
tional group included VEGF, Id1, Madh5, beta-catenin and
other genes. These genes are recognized in the literature
for their role in osteoblastic differentiation in addition to
their role in angiogenesis [42-45]. The expressed genes'
function in angiogenesis implies that MSCs induce or
attract formation of blood vessels. In addition, examining
the human and mouse orthologs revealed ECM structural
constituents including proteins that build up the base-
ment membrane, like collagens IV, V, VI and  laminin.
Expression of these genes can indicate a potential for an
endothelial differentiation.
Genes repressed following Dex treatment in cells derived
from young rats (Cluster D) are related to adipocyte differ-
entiation, regulation and function. This function included
the two transcription factors PPARγ and CEBPα, which are
essential for adipocyte differentiation. PPARγ maintains
adipogenesis and is necessary for early differentiation and
survival of mature adipocytes [46]. CEBPα  is activated
later than PPARγ during adipogenesis [47] and lack of this
TF results in non-functional adipocytes [48]. These factors
are sufficient for adipogenic differentiation in non-adipo-
genic mesenchymal cells [49] including myoblasts [50].
Adipogenesis and osteogenesis represent two divergentBMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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pathways of differentiation from the mesenchymal stem
cells. Genes up-regulated in osteogenesis, such as Msx2,
repress adipogenesis by inhibition of PPARγ and CEBPα
[49]. Alternatively, PPARγ inhibits osteogenesis suppress-
ing the osteoblastic phenotype [51]. We have demon-
strated an interchanging relationship between
osteogenesis and adipogenesis affected by Dex. Dex
increased beta-catenin in the cells derived from young rats
that is concurrent with an increase in osteoblastic poten-
tial of these cells. Beta-catenin represses adipogenesis [52]
and induces osteogenesis [45]. Thus, the Dex effect of sup-
pressing the adipogenesis (Table 2, cluster D) and increas-
ing the osteogenesis (Table 1, cluster A) suggests that beta-
catenin plays a role in the Dex dependent modulation of
the two lineages.
The genes repressed in both ages (Cluster F, Table 2)
include proliferation related genes, which complement
the genes induced in cells from both age groups. We also
observed a decrease in adipogenesis related genes, and in
catabolic peptidases, indicating an anabolic effect of Dex.
In addition, Dex decreased the expression of genes related
to defense and immune response (Table 2). Dex is known
to decrease the expression of immune genes, mostly tested
on lymphocytes [21]. Mesenchymal cells have been
shown to express immune cell markers, known to pro-
RT-PCR analysis of genes related to bone remodeling, muscle development and lipid binding and metabolism Figure 3
RT-PCR analysis of genes related to bone remodeling, muscle development and lipid binding and metabolism. 
(A) – bone remodeling include BMP4, Biglycan, BSP, (B) – muscle development include Actin, Desmin and (C) – lipid binding 
and metabolism include AP-2, LPL, Adipsin. (A-C) – Y axis represents the gene expression level (normalized to G3PDH) of the 
YU (light blue bars), YT (blue bars), OU (pink bars), and OT (purple bars). T-test comparing expression level in treated and 
untreated age-matched samples was performed – * p value < 0.005, expression levels of all genes analyzed except Biglycan are 
significant with p value < 0.05. (D) – Y axis represents the ratio between treated and untreated cells from young (blue bars) 
and old (purple bars) rats.
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Table 3: Gene array analysis for adipogenesis, osteogenesis and myogenesis pathways
GeneID Name Probe_ID Fold change
YT/YU OT/OU
Cluster A
Angiogenesis
114111 a vascular endothelial growth 
factor
1368463_at 3.452121 1.502053
24617 a Serine/cysteine proteinase 
inhibitor1
1368519_at 5.822078 0.845776
25261 a Inhibitor of DNA binding 1, 
helix-loop-helix protein
1387028_a_at 3.49452 0.986531
29452 a Endothelial PAS domain 
protein 1
1369703_at 5.615 1
64032 a connective tissue growth 
factor
1367631_at 2.58613 1.079194
84353 b beta-catenin 1369733_at 2.459261 1.906824
Bone Remodeling
24477 integrin binding 
sialoprotein
1368416_at 7.7875 1
56813 parathyroid hormone 
receptor 1
1370259_a_at 2.66125 1.123853
59328 MAD homolog 5 
(Drosophila)*
1369276_at 2.14625 1.970041
79110 matrix extracellular 
phosphoglycoprotein
1387330_at 3.37375 0.997506
Cluster C
Cytoskeleton & Muscle Development
24582 ac myosin heavy chain 11 1370896_a_at 5.571237 4.653653
24851 ac tropomyosin 1, alpha 1370288_a_at 4.89204 5.13257
25365 Actin, gamma 2 1386869_at 4.126485 5.083472
29437 ac Actin alpha 1 1369928_at 17.85533 9.397908
64362 ac Desmin 1367600_at 2.398671 2.356318
114489 d dystroglycan 1 1389105_at 5.441386 7.678867
303468 bd Sarcoglycan 1372240_at 2.9525 2.708798
25485 myosin IC 1369779_at 5.11 2.61875
81531 profilin II 1367970_at 3.62625 4.4225
24170 Adducin 1, alpha 1388487_at 2.475238 2.510223
Cell growth & Cell Cycle
24842 tumor protein p53 1367830_a_at 2.264291 2.543204
64457 d N-myc downstream 
regulated 4
1370229_at 4.279081 3.103067
29576 d WNT1 inducible signaling 
pathway protein 2
1369484_at 7.956218 2.918245
24183 adenylate kinase 1 1370011_at 4.118338 4.754549
25163 cyclin dependent kinase 
inhibitor 2A
1369194_a_at 14.86273 8.253055
50594 neuroblastoma, 
suppression of 
tumorigenicity 1
1387004_at 3.827506 2.863581
58919 cyclin D1 1371150_at 3.147613 2.447929
64363 v-raf murine sarcoma 3611 
viral oncogene homolog 1
1388305_at 2.02 2.018793
83570 c-fos induced growth 
factor (vascular endothelial 
growth factor D)
1387709_at 11.6725 3.355
94201 cyclin-dependent kinase 4 1372739_at 2.388806 2.154783
Cluster D
Adipocyte Differentiation
24252 CCAAT/enhancer binding 
protein, alpha
1369658_at 0.460345 0.627943
25664 peroxisome proliferator 
activated receptor, gamma
1369179_a_at 0.291579 0.79108BMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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duce supportive stroma that regulates the HIM in the dif-
ferentiation of the immune cells [53,54]. Thus, the
decrease in immune-related genes may be related to the
stromal function. This is strengthened by the fact that
Cluster F
Lipid Binding & Transport
140868 fatty acid binding protein 5 1370281_at 0.144064 0.4143
170538 protein kinase C, delta 1387114_at 0.365549 0.470085
25023 protein kinase C, beta 1 1370585_a_at 0.028032 0.061769
25056 retinol binding protein 1 1367939_at 0.468695 0.471976
25728 apolipoprotein E 1370862_at 0.308694 0.087332
25292 apolipoprotein C-I 1368587_at 0.175235 0.329354
29184 cd36 antigen 1386901_at 0.055742 0.035525
29510 phosphatidylcholine 
transfer protein
1387058_at 0.346607 0.226442
79124 ZAP 36/annexin IV 1389305_at 0.488443 0.480585
79451 adipocyte protein aP2 1368271_a_at 0.039507 0.01239
Catabolism & Lysosomal Enzymes
117033 ac matrix metalloproteinase 
12
1368530_at 0.02401 0.214259
171052 ac matrix metalloproteinase 
13
1388204_at 0.155018 0.195806
25335 ac matrix metalloproteinase 7 1368766_at 0.150338 0.189753
24331 ac elastase 1 1387819_at 0.108743 0.2376
25166 ac caspase 1 1369186_at 0.255206 0.175345
171329 ac ubiquitin specific protease 
15
1370460_at 0.295028 0.444408
24539 ac lipoprotein lipase 1386965_at 0.016611 0.039975
54249 bd Adipsin 1388602_at 0.18685 0.047754
313387 bd ubiquitin specific protease 
1
1376687_at 0.417153 0.373377
24944 ac lysosomal membrane 
glycoprotein 2
1370010_at 0.430907 0.347294
Ras protein signal transduction
114203 adaptor protein with 
pleckstrin homology and 
src homology 2 domains
1368605_at 0.2262 0.175548
24525 Kirsten rat sarcoma viral 
oncogene homologue 2 
(active)
1370035_at 0.312723 0.375405
24605 neuroblastoma RAS viral 
(v-ras) oncogene homolog
1372032_at 0.191657 0.238384
81504 growth factor receptor 
bound protein 2
1368386_at 0.373241 0.484997
Defense Response
113959 complement component 5, 
receptor 1
1368742_at 0.234295 0.239768
116591 Fc receptor, IgG, low 
affinity III
1367850_at 0.292948 0.310885
24223 a beta-2 microglobulin 1371440_at 0.13671 0.16094
24494 ac interleukin 1 beta 1398256_at 0.055097 0.172791
56822 ac CD86 antigen 1387627_at 0.206497 0.402268
25599 ac CD74 antigen 1367679_at 0.011698 0.040091
60350 ac CD14 antigen 1368490_at 0.469431 0.412767
24930 a CD8 antigen, alpha chain 1369877_at 0.36815 0.4273
24931 a CD8 antigen, beta chain 1387739_at 0.203248 0.376336
24932 ac CD4 antigen 1369483_at 0.204226 0.301498
The fold change are of treated versus untreated cells from young (3 month) or old (15 month) rats. In genes that have multiple probe sets, a 
representative probe set was displayed.
a) gene was selected with the relevant function in both rat genes and mouse orthologs
b) gene was selected with the relevant function in mouse orthologs,
c) gene was selected with the relevant function in both rat genes and human orthologs
d) gene was selected with the relevant function in human orthologs,
*) MAD homolog 5 appears also under the function of angiogenesis
Table 3: Gene array analysis for adipogenesis, osteogenesis and myogenesis pathways (Continued)BMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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repressed genes also included sub-sets of membranous
proteins and genes related to antigen processing and pres-
entation (human and mouse orthologs). Hormonal mod-
ulation affects cells signaling. We identified repression of
RAS pathway, which included the genes Nras, Kras2, Grb2
and Aps and also play a role in control of cell proliferation
and can also repress differentiation in the myogenic [55]
and osteogenic [56] pathways. Grb2  adaptor protein
mediates the proliferative anti-myogenic differentiation
action of Met  (HGF Recptor) [57], FGFR  [58] and is
involved in signaling of Dystrophin complex [59]. The
decrease in Ras signaling genes is complimentary to the
proliferation and differentiation genes induced by Dex
(Table 1, Cluster C) and indicates a decrease in cell prolif-
eration, which is coupled with myoblastic or osteoblastic
differentiation.
Suppression of adipogenic differentiation was noted by
decrease of genes related to lipid binding, lipid transport
and diacylglycerol binding including representative genes,
such as FABP-4 (aP-2) [60,61] and lipoprotein lipase (Lpl)
[62]. Adipsin repression marked the catabolism function
of adipocytes [63]. Protein Kinase C isoforms are associ-
ated with various differentiation pathways. PKC repres-
sion increases myogenesis [64] and as a mediator of PTH
receptor actions this enzyme is known to increase osteo-
genesis and repress adipogenesis in mesenchymal cell
lines [65]. PKC is also associated with inducing osteoblast
production of IL-6 [66] which promotes bone resorption.
Thus, the decrease in PKC induces mesenchymal differen-
tiation to the myogenic pathway.
Catabolic peptidases and lysosomal proteins decreased
following Dex treatment. Matrix metalloproteinases 7,9,12
& 13, genes which play a role in collagen catabolism and
bone remodeling [67] were included in this group. Addi-
tional genes were lysosomal proteases important in lym-
pho-myeloid cells and cathepsins. Cathepsin K is the main
protease in osteoclastic function that plays a role in bone
resorption [68]. The decrease in expression of these genes
indicates a lower rate of bone resorption, which conse-
quently results in an increase in gene related to bone for-
mation mediating the effects of Dex.
Conclusion
Aging affects the bone marrow microenvironment in mul-
tiple ways, including a decrease in the differentiation
potential of cells associated with decrease in bone forma-
tion. To better understand molecular mechanisms govern-
ing the cellular changes we profiled the response of ex vivo
cultured stromal cells to Dex and compared cells derived
from young and old rats. The gene expression profiling
highlights age-independent modes of Dex action which
overlapped between the two age groups. While this study
demonstrates the effect of Dex on in ex vivo cultured cells,
it would be interesting to expand the scope to include the
in vivo effects of Dexamethasone. In general, pattern of
expression included repression of proliferation and
induction of differentiation. The RNA analyzed was
extracted from pooled samples from multiple animals, a
method which has been proven to reduce variability, rec-
ommended when using a small number of microarrays
[69]. It is possible that additional replicates would further
refine these gene lists and may alter some of our conclu-
sions. Continuing research and verification of this inter-
esting subject are required in the future. Specifically, we
catalogued genes related to induction of myogenic differ-
entiation coupled with a decrease in adipogenesis. We
demonstrated Dex-related decrease in immune response
genes; Dex decreased genes that regulate bone resorption
and induced osteoblastic differentiation. The high
throughput analysis enlightens the effect of Dex and the
relationship between osteogenesis and adipogenesis in
the bone marrow due to aging. We have also demon-
strated the plasticity of cells and the reciprocal relation-
ship of the osteogenic, myogenic and adipogenic lineages
in the bone marrow.
Methods
Ex vivo cultures of mesenchymal cells
Mesenchymal stromal cells (MSCs) were cultured from
female Wistar rats. Cells were cultured in Dulbecco's mod-
ified essential Medium (DMEM) with 10% heat-inacti-
vated fetal calf serum (FCS) (Gibco, USA) [4]. The bone
marrow cells were harvested from young rats (3 months
old) and old rats (15 months old). Cells were collected as
previously described [15]. In brief, the bone marrow cells
were flushed from the long bone collected and prepared
for single cells suspension. Cells pooled from six rats in
each group were cultured in 75 cm2 flasks (Falcon, USA)
containing 20 ml of growth medium, Dulbecco's Modi-
fied Essential Medium (DMEM) containing 10% heat-
inactivated fetal calf serum (FCS). Under these conditions,
the hematopoietic cells died and the cultures finally
remained only with cells forming the adherent stromal
fibroblast-like layer. Cells were plated and after one week
of culturing were trypsinized, single cell suspensions were
re-cultured for 7 days and were grown in absence or pres-
ence of 10-8 M Dexamethasone (Dex). On day 14 cells
were harvested for RNA extraction and created four sam-
ples – young untreated (1 – YU), old untreated (2 – OU),
young treated (3 – YT) and old treated cells (4 – OT).
RNA analysis and microarrays
Total RNA were extracted from the design four experimen-
tal groups. Each group is composed from multiple ani-
mals, a method which has been proven to reduce
variability, and is recommended when using a small
number of microarrays [69]. RNA was extracted using the
TRIzol and cRNA prepared according to Affymetrix proto-BMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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cols. Gene expression was measured by hybridization to
Affymetrix RAE230A Gene Chip DNA microarrays
(Affymetrix, Santa Clara, CA, USA), containing 15,766
probe sets (PS) (excluding controls), comprising 14,280
Unigene clusters (11,497 Gene IDs, 4,699 full-length
transcripts). The data is available as accession GSE3339 of
the Gene Expression Omnibus (GEO).
Gene expression analysis
Total RNA extracted from cultured cells following ex vivo
expansion was reverse transcribed using avian myeloblas-
tosis virus reverse transcriptase (AMV-RT) and oligo-dT to
generate cDNA that served as a template for the polymer-
ase chain reaction (PCR) (Takara Shuzo Co. Ltd., Japan)
with gene specific primers (Table 4). The integrity of the
RNA, the efficiency of the RT reaction and the quality of
cDNA subjected to the RT-PCR was controlled by amplifi-
cation of Gluteraldehyde-3-Phosphate Dehydrogenase
(G3PDH) (Clontech, Palo Alto, CA). The reaction prod-
ucts were separated by electrophoresis in 1% agarose gels
(SeaKem GTG, FMC, USA) in Tris Borate EDTA (TBE)
buffer. The amplified DNA fragments were stained by
ethidium bromide, and their optical density was meas-
ured using Bio Imaging System, BIS 202D and analyzed
using "TINA" software. PCR amplification was performed
at least twice and subjected to semi-quantitative analyses
by comparison of OD of gene-specific PCR products nor-
malized to the OD of co-amplified G3PDH-PCR product
in four groups YO, OU, YT and OT.
The computerized data analysis
We used the MAS 5.0 algorithm to provide a baseline
expression level and detection for each PS. PS were filtered
according to the following criteria: (a) at least one sample
was detected as Present (P) when calculating MAS 5.0
detection call; and (b) at least one sample had an expres-
sion level higher than 20. The expression levels of 10290
retained PS normalized using the Quantile Normalization
method, provided by the software package 'affy' (version
1.5.8) [70], available as part of the Bioconductor project.
For every PS, the ratio between expression level of the
treated and untreated samples was calculated. PS were
analyzed when the expression ratio at least 2 fold, in
either age group. Gene expression of cells cultured from
young rats (young treated versus young untreated) was
compared to cells from old rats (old treated versus old
untreated). After filtering the PS were standardized by
transforming each expression pattern to have a mean of 0
and a variance of 1.
Clustering analysis
We used a rule-based clustering method on the PS that
were differentially expressed when the fold change was at
least two and were analyzed for either increasing or
decreasing expression between Dex-treated and untreated
cells. For every PS, the ratio between expression level of
the treated and untreated samples was calculated. Every
PS was graded as increased, decreased or unchanged. The
young grade (YT/YU) was compared to the old grade (OT/
OU), and this determined the cluster. This method
resulted in 4060 PS, clustered in 8 distinct clusters. This
clustering method separated increased and decreased PS
due to Dex, and highlighted difference between old and
young rats. Partial data is discussed in this paper and com-
plete lists of functions and genes are available upon
request.
Table 4: Primers used for RT-PCR amplification
Gene Primers Size of PCR Product
ADIPSIN F: GAGGCGGCTGTATGTGTTG
R: AGGCATTGTGGGAGAGCTTA
337 bp
LPL F: CCCTAAGGACCCCTGAAGAC
R: AGCTGGATCCAAGCCAGTAA
401 bp
BIGLYCCAN F: TGATGAGGAGGCTTCAGGTT
R: ACTTTGCGGATACGGTTGTC
413 bp
BMP4 F: ATGAGGGATCTTTACCGGCT
R: TTTATACGGTGGAAGCCCTG
293 bp
BSP F: AGGGGAATGAAGACCAGGAG
R: TTCGTCCTCATAAGCTCGGTA
607 bp
GR F: ACCACAGACCAAAGCACCTT
R: AAGGGATGCTGTATTCATGTCA
444 bp
DESMIN F: CCGAGCTCTACGAGGAGGA
R: ACCTGCTGTTCCTGAAGCTG
321 bp
ACTIN GAMMA2 F: GGAGAAGATCTGGCACCACT
R: TGATCCACATTTGCTGGAAG
826 bp
AP-2 F: TGTCTCCAGTGAAAACTTCGATGA
R: ACTCTTGTGGAAGTCACGCCTTT
350 bp
G3PDH F: ACCACAGTCCATGCCATCAC
R: TCCACCACCCTGTTGCTGTA
450 bpBMC Genomics 2006, 7:95 http://www.biomedcentral.com/1471-2164/7/95
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Gene Ontology analysis
The clusters were analyzed for Gene Ontology (GO)
annotations appearing in a statistically significant manner
in the cluster, when compared to a background. The back-
ground was comprised of all expressed genes – a list of all
genes expressed in at least one of the four samples. For
each GO term the number of genes with this term in a
cluster was compared to the number of genes with this
term in the background. Additionally the ratio between
number of genes in the cluster and number of gene in the
background was calculated. The two ratios served to calcu-
late a p-value, and terms with a p-value lower than 0.01
were listed. The analysis was done using GO Tree Machine
(GOTM) [71], the 08/09/04 version. For verification, the
same functional analysis was done on Human and Mouse
orthologs (provided by Affymetrix 29/07/04), using the
EXPANDER software suite [72].
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